国家: 爱尔兰
语言: 英文
来源: HPRA (Health Products Regulatory Authority)
DIPHTHERIA TOXOID, TETANUS TOXOID, PERTUSSIS TOXOID, FILAMENTOUS HAEMAGGLUTININ, PERTACTIN (PRN), FIMBRIAE TYPES 2 AND 3
Sanofi Pasteur MSD Ltd
J07AJ52
DIPHTHERIA TOXOID, TETANUS TOXOID, PERTUSSIS TOXOID, FILAMENTOUS HAEMAGGLUTININ, PERTACTIN (PRN), FIMBRIAE TYPES 2 AND 3
Suspension for Injection
Product subject to prescription which may not be renewed (A)
Pertussis, Purified Antigen, Combinations with Toxoids
Authorised
2016-06-03
PACKAGE LEAFLET: INFORMATION FOR THE USER TRIAXIS SUSPENSION FOR INJECTION IN PRE-FILLED SYRINGE Diphtheria, Tetanus, Pertussis (acellular, component) Vaccine (adsorbed, reduced antigen(s) content) READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU OR YOUR CHILD IS VACCINATED BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. - Keep this leaflet. You may need to read it again. - If you have any further questions, ask your doctor, pharmacist or nurse . - This vaccine has been prescribed for you or for your child only. Do not pass it on to others. - If you or your child get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. See section 4. WHAT IS IN THIS LEAFLET: 1. What TRIAXIS is and what it is used for 2. What you need to know before TRIAXIS is given to you or your child 3. How and when TRIAXIS is given 4. Possible side effects 5. How to store TRIAXIS 6. Contents of the pack and other information 1 WHAT TRIAXIS IS AND WHAT IT IS USED FOR TRIAXIS is a vaccine. Vaccines are used to protect against infectious diseases. They work by causing the body to produce its own protection against the bacteria that cause the targeted diseases. This vaccine is used to boost protection against diphtheria, tetanus and pertussis (whooping cough) in children from the age of 4 years, adolescents and adults, following a complete primary course of vaccination. LIMITATIONS IN THE PROTECTION PROVIDED TRIAXIS will only prevent these diseases if they are caused by the bacteria targeted by the vaccine. You or your child could still get similar diseases if they are caused by other bacteria or viruses. TRIAXIS does not contain any live bacteria or viruses and it cannot cause any of the infectious diseas 阅读完整的文件
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Triaxis, suspension for injection in a pre-filled syringe 2 QUALITATIVE AND QUANTITATIVE COMPOSITION 1 dose (0.5 mL) contains: Diphtheria Toxoid Not less than 2 IU* (2 Lf) Tetanus Toxoid Not less than 20 IU* (5 Lf) Pertussis Antigens Pertussis Toxoid 2.5 micrograms Filamentous Haemagglutinin 5 micrograms Pertactin 3 micrograms Fimbriae Types 2 and 3 5 micrograms Adsorbed on aluminium phosphate 1.5 mg (0.33 mg aluminium) * As lower confidence limit (p = 0.95) of activity measured according to the assay described in the European Pharmacopoeia. This vaccine may contain traces of formaldehyde and glutaraldehyde which are used during the manufacturing process (see sections 4.3 and 4.4). For the full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Suspension for injection in pre-filled syringe. Triaxis appears as a cloudy white suspension 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS TRIAXIS is indicated for active immunization against tetanus, diphtheria and pertussis in persons from 4 years of age as a booster following primary immunization. The use of TRIAXIS should be determined on the basis of official recommendations. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Posology A single injection of one (0.5 mL) dose is recommended in all indicated age groups. TRIAXIS is a vaccine containing low-dose diphtheria-, tetanus- and pertussis-antigens indicated for booster vaccinations. When administering the vaccine, indications and dosing intervals according to the official recommendations should be considered for all antigens contained in the vaccine. Individuals with an incomplete, or no history of a primary series of diphtheria and tetanus toxoids should not be vaccinated with TRIAXIS. HEALTH PRODUCTS REGULATORY AUTHORITY _ 阅读完整的文件